Changes of bone mineral density and serum pentosidine during a 27-month follow-up of monthly minodronate in osteoporotic patients
- 20 March 2017
- journal article
- Published by Taylor & Francis Ltd in Endocrine Research
- Vol. 15, 1-9
- https://doi.org/10.1080/07435800.2017.1292527
Abstract
Monthly regimen of minodronate for osteoporosis more than two years has not been reported yet. The aim of this study is to elucidate the effect of monthly minodronate (M-MIN) on bone mineral density (BMD) and serum pentosidine (Pen) during 27 months.Keywords
This publication has 26 references indexed in Scilit:
- Three years of treatment with minodronate in patients with postmenopausal osteoporosisJournal of Bone and Mineral Metabolism, 2011
- The relationship between the chemistry and biological activity of the bisphosphonatesBone, 2011
- The kidney and bisphosphonatesBone, 2011
- Urinary pentosidine improves risk classification using fracture risk assessment tools for postmenopausal womenJournal of Bone and Mineral Research, 2011
- Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatmentJournal of Bone and Mineral Metabolism, 2010
- Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronateOsteoporosis International, 2008
- Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fracturesJournal of Bone and Mineral Metabolism, 2008
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisThe New England Journal of Medicine, 2007
- Plasma Pentosidine Is Associated with Inflammation and Malnutrition in End-Stage Renal Disease Patients Starting on Dialysis TherapyJournal of the American Society of Nephrology, 2003
- Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosisJournal of Bone and Mineral Research, 1996